Patient-Reported Symptoms for Esophageal Cancer Patients Undergoing Curative Intent Treatment

Gupta, Vaibhav; Allen-Ayodabo, Catherine; Davis, Laura; Zhao, Haoyu; Hallet, Julie; Mahar, Alyson; Ringash, Jolie; Kidane, Biniam; Darling, Gail; Coburn, Natalie

doi:10.1016/j.athoracsur.2019.08.030

Cited by 22 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the characteristics associated with symptom severity, female sex was consistently present. 18 In a study of 120 patients with colorectal cancer that completed PROMs for symptom burden, the severity score for worrying and lack of energy was significantly higher in women compared with men. 19 Similarly, in a cohort of more than 400 patients with melanoma, female patients reported significantly more anxiety over a 2-year prospective follow-up assessment period compared with male patients.…”

Section: Pros In Oncologymentioning

confidence: 99%

Sex-specific and gender-specific aspects in patient-reported outcomes

et al. 2020

View full text Add to dashboard Cite

Patient-reported outcomes (PROs) are important tools in patient-centred medicine and allow for individual assessment of symptom burden and aspects of patients’ quality of life. While sex and gender differences have emerged in preclinical and clinical medicine, these differences are not adequately represented in the development and use of patient-reported outcome measures. However, even in personalised approaches, undesirable biases may occur when samples are unbalanced for certain characteristics, such as sex or gender. This review summarises the current status of the literature and trends in PROs with a focus on sex and gender aspects.

show abstract

Section: Pros In Oncologymentioning

confidence: 99%

Sex-specific and gender-specific aspects in patient-reported outcomes

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 1 , 2 Patients with esophageal cancer usually experience difficulty in swallowing, chest pain, weight loss, worsening indigestion, coughing, and other severe symptoms. 3 , 4 Recent epidemiological investigations have revealed that esophageal cancer development is closely associated with multiple risk factors such as genetic mutations, smoking, alcohol abuse, obesity, frequent drinking of hot beverages, radiation, as well as pathogenic conditions including gastroesophageal reflux disease, Barrett's esophagus, and achalasia. 1 , 5 , 6 The pathogenesis of esophageal cancer is mediated by an accumulation of oncogene activation and tumor suppressor gene inactivation, which results in increased cell proliferation, decreased apoptosis, as well as increased cell migration capacity and angiogenesis, which contribute to esophageal cancer metastasis.…”

Section: Introductionmentioning

confidence: 99%

MiR-495 Inhibits Cisplatin Resistance and Angiogenesis in Esophageal Cancer by Targeting ATP7A

Yongqin

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: Cancer resistance to chemotherapy is closely associated with changes in transporter systems. In this study, we investigated the possible regulation of 1 copper ion transporter (ATP7A; ATPase copper transporting alpha) by microRNA miR-495 and its implications in cisplatin resistance and angiogenesis in esophageal cancer. Methods: MiR-495 and ATP7A mRNA expression in clinical tissue samples and 2 cancer cell lines (Eca-109 and TE1) were detected by quantitative real-time polymerase chain reaction. The levels of miR-495 and ATP7A expression in Eca-109 and TE1 cells were increased by transfection with miR-495 mimics and ATP7A-overexpression vectors. Cell proliferation, apoptosis, and angiogenesis were assessed by CCK-8, flow cytometry, and tube formation assays, respectively. The levels of TNF-α and VEGF in cell culture supernatants were detected by enzyme linked immunosorbent assay, and in situ expression of NLRP3 was measured by immunofluorescence. The binding of miR-495 to ATP7A sequences was verified by dual luciferase reporter assays. Results:ATP7A expression was significantly increased, while miR-495 expression was decreased in the cancer tissues of esophageal cancer patients. MiR-495 mimics decreased the proliferation and promoted the apoptosis of cisplatin-resistant Eca-109 and TE1 cells. Furthermore, tube formation by human umbilical vein endothelial cells, TNF-α and VEGF secretion, and the levels of MRP1, ABCG1, ABCA1, and NLRP3 expression in cisplatin-resistant Eca-109 and TE1 cells were all reduced by miR-495 mimics. MiR-495 was shown to directly bind to ATP7A gene sequences to repress ATP7A expression in Eca-109 and TE1 cells. ATP7A overexpression substantially abrogated the changes in proliferation, apoptosis, angiogenesis, and above-mentioned gene expression in cisplatin-resistant Eca-109 and TE1 cells. Conclusions: MiR-495 suppressed cisplatin resistance and angiogenesis in esophageal cancer cells by targeting ATP7A gene expression.

show abstract

“…At our radiation oncology clinic, we have previously utilized the revised ESAS (ESAS-r-CSS) to explore symptom clusters for patients receiving palliative and definitive intent radiotherapy [19] and with expanded use across different oncology clinics we have reported our results on ESAS-driven screening for anemia [20]. The use of the ESAS questionnaire has also been explored in patients receiving definitive radiotherapy [21], particularly for breast [22] and esophageal cancer [23] as well as in sarcoma patients receiving chemotherapy [24]. Finally, studies have emphasized the use of symptom assessment tools such as ESAS to the reduce healthcare system burden due to treatment delays and costs of emergency room visits for breakthrough cancer pain management [25,26].…”

Section: Introductionmentioning

confidence: 99%

Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma

Palm

Jim

Boulware

et al. 2020

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Background and purpose: Retroperitoneal sarcoma (RPS) is a rare, complex disease requiring multidisciplinary management. We have previously reported that use of the Revised Edmonton Symptom Assessment Scale (ESAS-r-CSS) allows for proactive symptom management, and we sought to report the results of ESAS-r-CSS screening during pre-operative radiotherapy (RT) for a cadre of patients with RPS. Materials and methods: We reviewed records of 47 patients with RPS evaluated at our institution between 2015 and 2018. Of this group, 29 non-metastatic patients were treated with definitive intent neoadjuvant RT with at least 2 weekly ESAS-r-CSS reports. A generalized estimating equation model was used to compare 13 symptoms during weekly on-treatment visits compared to baseline scores at week 1 of RT. Additionally, covariate effects of age, gender, dose, tumor size and location were assessed. Results: The population was predominantly male (66%) with median age of 65 years, KPS of 90, and tumor size of 12.8 cm. ESAS scores significantly decreased for anxiety at week 3 (P = 0.01), and pain at week 5 (P = 0.01). Worse constipation was reported at week 2 (P = 0.02). In an exploratory covariate analysis, female gender, age, high dose, and larger tumor size were associated with worse ESAS scores across all time points. Conclusion: Patient reporting of symptoms during radiotherapy through weekly ESAS-r-CSS facilitates timely management in patients with this unique tumor type. Expectant care during RT offers the opportunity to minimize symptom progression or treatment interruptions in a population that generally has worsening side effects.

show abstract

Patient-Reported Symptoms for Esophageal Cancer Patients Undergoing Curative Intent Treatment

Cited by 22 publications

References 27 publications

Sex-specific and gender-specific aspects in patient-reported outcomes

Sex-specific and gender-specific aspects in patient-reported outcomes

MiR-495 Inhibits Cisplatin Resistance and Angiogenesis in Esophageal Cancer by Targeting ATP7A

Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma

Contact Info

Product

Resources

About